- |||||||||| lomibuvir (VX 222) / Trek Therapeutics, Metopirone (metyrapone) / HRA Pharma, Torisel (temsirolimus) / Pfizer
Preclinical, Journal: Drug repurposing approach against chikungunya virus: an in vitro and in silico study. (Pubmed Central) - May 18, 2023
Furthermore, in silico molecular docking studies performed by targeting CHIKV structural and non-structural proteins revealed that these drugs can bind to structural protein targets such as envelope protein, and capsid, and non-structural proteins NSP2, NSP3 and NSP4 (RdRp). Findings from in vitro and in silico studies reveal that these drugs can suppress the infection and replication of CHIKV and further in vivo studies followed by clinical trials are warranted.
- |||||||||| lomibuvir (VX 222) / Trek Therapeutics, Vitekta (elvitegravir) / Japan Tobacco, Gilead
FDA event, Preclinical, Journal: A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2. (Pubmed Central) - Oct 28, 2022
Results revealed that five compounds, viz., resveratrol, doxorubicin, lomibuvir, elvitegravir, and enalaprilat, have significant anti-DENV activity. Further, molecular docking studies showed that these drugs can interact with a variety of protein targets of DENV, including the glycoprotein, the NS5 RdRp, NS2B-NS3 protease, and NS5 methyltransferase The in vitro and in silico results, therefore, reveal that these drugs have the ability to decrease DENV-2 production, suggesting that these drugs or their derivatives could be attempted as therapeutic agents against DENV infections.
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, lomibuvir (VX 222) / Trek Therapeutics
Trial termination, Combination therapy: A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Na (clinicaltrials.gov) - Feb 27, 2014
P2, N=152, Terminated,
Future clinical studies examining these drugs might come to conclude, which can be more useful to inhibit COVID-19 progression. Active, not recruiting --> Terminated; Study discontinued
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, lomibuvir (VX 222) / Trek Therapeutics
Trial completion, Combination therapy: VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C (clinicaltrials.gov) - Feb 26, 2014
P2, N=64, Completed,
Active, not recruiting --> Terminated; Study discontinued Active, not recruiting --> Completed
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, lomibuvir (VX 222) / Trek Therapeutics
Trial completion: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis (clinicaltrials.gov) - Feb 25, 2014
P2, N=103, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, lomibuvir (VX 222) / Trek Therapeutics
New P2 trial: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis (clinicaltrials.gov) - Jan 23, 2012
P2, N=103, Completed,
|
